Aripiprazole is an atypical antipsychotic used for schizophrenia, manic and mixed episodes associated with bipolar I disorder and as adjunctive therapy for major depressive disorder. It functions as a partial agonist at dopamine D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptor. The most recent results obtained from scientific research showed that dopaminergic mechanisms are involved in motivation, reward, and reinforcement of substance abuse. The use of aripiprazole and partial dopamine agonists could represent a novel strategy for normalizing dopamine neurotransmission. Many studies in the last few years have highlighted aripiprazole as a potential candidate for the treatment of different types of substance dependence.
Do you have any clinical experience?
Thank you
CNS Drugs. 2014 Feb;28(2):171-83. doi: 10.1007/s40263-013-0134-2.
Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.
McKeage K1.
Drugs. 2004;64(15):1715-36.
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T1, Perry CM.
In Finland it is recommended for persons with schizophrenia under 15 years old.
The dopamine hypothesis in schizophrenia is rather old:
The dopamine hypothesis of schizophrenia. A critical analysis.
Luchins D.
Neuropsychobiology. 1975;1(6):365-78.
Dopamine nerve terminals in the rat limbic cortex: aspects of the dopamine hypothesis of schizophrenia.
Hökfelt T, Ljungdahl A, Fuxe K, Johansson O.
Science. 1974 Apr 12;184(4133):177-9.
Maybe this can be helpful for you:
https://clinicaltrials.gov/ct2/show/NCT00208169
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs